INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
The primary goal of the collaboration is joint research into trending and next-generation molecules
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Subscribe To Our Newsletter & Stay Updated
